Skip to content

Study · Animal study (in vivo) · 2003

7 results

[Pharmacological correction of immuno-metabolic disorders with the peptide Gly-His-Lys in hepatic damage induced by tetrachloromethane].

Smakhtin MIu, Konoplia AI, Sever'ianova LA, Shveĭnov IA

Patologicheskaia fiziologiia i eksperimental'naia terapiia1 Apr 2003Cited by 1 (Europe PMC)

PMID12838768 (opens in a new tab)PepBankPUB-12838768
Publisher pageAsk about this study
Jump to 7 results

Summary

The text of this summary is not shown here, because the article license does not allow reuse. Read it at the source (opens in a new tab)

Text rights: Publisher copyright. Results still quote short attributed sentences.

Results from this study7

7 results from studies that gave the peptide. No result from this study comes from people.

  1. 01AnimalAnimal study (in vivo)Efficacy outcome

    In acute toxic liver damage, Gly-His-Lys at 2.5 mu/kg raised the hepatocyte mitotic index.

    In plain wordsIn animals with toxic liver damage, Gly-His-Lys at 2.5 mu/kg increased hepatocyte division.

    Peptide
    GHK (glycyl-L-histidyl-L-lysine)
    Outcome
    IncreaseHepatocyte mitotic index
    Study

    n: not reported in source

    acute toxic liver damage
    Outcome group
    Liver fat and liver function · Liver
    Studied dose
    2.5 mu/kg · intraperitoneal · 10-dayAs given in this study.

    Source sentences

    Summary
    10-day intraperitoneal administration of the tripeptie Gly-His-Lys in doses 2.5 and 150 mu/kg raises of mitotic index of hepatocytes in acute toxic damage to the liver.
  2. 02AnimalAnimal study (in vivo)Efficacy outcome

    In acute toxic liver damage, Gly-His-Lys at 150 mu/kg raised the hepatocyte mitotic index.

    In plain wordsIn animals with toxic liver damage, Gly-His-Lys at 150 mu/kg increased hepatocyte division.

    Peptide
    GHK (glycyl-L-histidyl-L-lysine)
    Outcome
    IncreaseHepatocyte mitotic index
    Study

    n: not reported in source

    acute toxic liver damage
    Outcome group
    Liver fat and liver function · Liver
    Studied dose
    150 mu/kg · intraperitoneal · 10-dayAs given in this study.

    Source sentences

    Summary
    10-day intraperitoneal administration of the tripeptie Gly-His-Lys in doses 2.5 and 150 mu/kg raises of mitotic index of hepatocytes in acute toxic damage to the liver.
  3. 03AnimalAnimal study (in vivo)Efficacy outcome

    In toxic liver damage, Gly-His-Lys at 1.5 mu/kg corrected hepatocyte functional activity.

    In plain wordsIn animals with liver damage, Gly-His-Lys at 1.5 mu/kg corrected hepatocyte functional activity.

    Peptide
    GHK (glycyl-L-histidyl-L-lysine)
    Outcome
    Direction not reportedHepatocyte functional activity
    Study

    n: not reported in source

    acute toxic liver damage
    Outcome group
    Liver fat and liver function · Liver
    Studied dose
    1.5 mu/kg · intraperitoneal · 10-dayAs given in this study.

    Source sentences

    Summary
    In the dose 1.5 mu/kg this peptie corrects both functional activity of hepatocytes and immunological responsiveness.
  4. 04AnimalAnimal study (in vivo)Efficacy outcome

    In toxic liver damage, Gly-His-Lys at 1.5 mu/kg corrected immunological responsiveness.

    In plain wordsIn animals with liver damage, Gly-His-Lys at 1.5 mu/kg corrected immune responsiveness.

    Peptide
    GHK (glycyl-L-histidyl-L-lysine)
    Outcome
    Direction not reportedImmunological responsiveness
    Study

    n: not reported in source

    acute toxic liver damage
    Outcome group
    Immune response · Immune and inflammation
    Studied dose
    1.5 mu/kg · intraperitoneal · 10-dayAs given in this study.

    Source sentences

    Summary
    In the dose 1.5 mu/kg this peptie corrects both functional activity of hepatocytes and immunological responsiveness.
  5. 05AnimalAnimal study (in vivo)Efficacy outcome

    In toxic liver damage, Gly-His-Lys at 150 mu/kg had a more potent immunosuppressive action.

    In plain wordsIn animals with liver damage, Gly-His-Lys at 150 mu/kg had a more potent immune-suppressing effect.

    Peptide
    GHK (glycyl-L-histidyl-L-lysine)
    Outcome
    IncreaseImmunosuppression
    Study

    n: not reported in source

    acute toxic liver damage
    Outcome group
    Immune response · Immune and inflammation
    Studied dose
    150 mu/kg · intraperitoneal · 10-dayAs given in this study.

    Source sentences

    Summary
    In a dose of 150 mu/kg the peptie has a more potent immunosuppressive action and deteriorates biochemical indices of blood serum as well as dystrophic changes in the liver.
  6. 06AnimalAnimal study (in vivo)Safety outcome

    In toxic liver damage, Gly-His-Lys at 150 mu/kg deteriorated serum biochemical indices.

    In plain wordsIn animals with liver damage, Gly-His-Lys at 150 mu/kg worsened serum biochemical indices.

    Peptide
    GHK (glycyl-L-histidyl-L-lysine)
    Outcome
    Direction not reportedSerum biochemical indices
    Study

    n: not reported in source

    acute toxic liver damage
    Outcome group
    Liver fat and liver function · Liver
    Studied dose
    150 mu/kg · intraperitoneal · 10-dayAs given in this study.

    Source sentences

    Summary
    In a dose of 150 mu/kg the peptie has a more potent immunosuppressive action and deteriorates biochemical indices of blood serum as well as dystrophic changes in the liver.
  7. 07AnimalAnimal study (in vivo)Safety outcome

    In toxic liver damage, Gly-His-Lys at 150 mu/kg worsened dystrophic liver changes.

    In plain wordsIn animals with liver damage, Gly-His-Lys at 150 mu/kg worsened liver degeneration.

    Peptide
    GHK (glycyl-L-histidyl-L-lysine)
    Outcome
    IncreaseLiver dystrophic changes
    Study

    n: not reported in source

    acute toxic liver damage
    Outcome group
    Liver fat and liver function · Liver
    Studied dose
    150 mu/kg · intraperitoneal · 10-dayAs given in this study.

    Source sentences

    Summary
    In a dose of 150 mu/kg the peptie has a more potent immunosuppressive action and deteriorates biochemical indices of blood serum as well as dystrophic changes in the liver.

AI wrote and checked these results. AI can make mistakes, so check important results against the source.

Version history

PepBank keeps every version of the data on this study. Status changes from Retraction Watch, Europe PMC and Crossref are listed with their source.

  1. Version 2Current

    14 Oct 2026, 05:02 UTC

    Study results updated

  2. Version 1

    14 Oct 2026, 01:46 UTC

    First added · source update from Europe PMC

Subjects

Terms as the source lists them.

Publication types

PepBank is a research reference. Talk to a doctor before you use any peptide.